Cell-based therapies reverse the heart failure-altered right ventricular proteome towards a pre-disease state
Open Access
- 13 November 2024
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 15 (1) , 1-15
Abstract
Congenital heart defects can lead to right ventricular (RV) pressure-overload and heart failure. Cell-based therapies, including mesenchymal stromal cells (MSCs) and c-kit positive cells (CPCs) have been studied clinically as options to restore heart function in disease states. Many studies have indicated these cells act through paracrine mechanisms to prevent apoptosis, promote cellular function, and regulate gene/protein expression. We aimed to determine the proteomic response of diseased hearts to cell therapy. We utilized a juvenile rat model of RV pressure overload created by banding the pulmonary artery (PAB). Two weeks post-banding, bone marrow-derived mesenchymal stromal cells (MSCs) and 3 populations of CPCs (nCPCs, cCPCs, ES-CPCs) were delivered to the RV free wall. RV function and cellular retention were measured for four weeks post-injection, at which point hearts were extracted and the RV was excised for liquid chromatography and tandem mass spectrometry. Resulting RV proteomes were compared and analyzed using systems biology and bioinformatics. Proteomic profiling identified 1156 total proteins from the RV, of which 5.97% were significantly changed after PAB. This disease-altered proteome was responsive to cellular therapy, with 72% of the PAB-altered proteome being fully or partially reversed by MSC therapy. This was followed by nCPCs (54%), ES-CPCs (52%), and cCPCs (39%). Systems biology and bioinformatics analysis showed MSC, nCPC, or ES-CPC cell therapy is associated with a decrease in predicted adverse cardiac effects. We also observed an effect of cell therapy on the non-altered RV proteome, however, this was associated with minor predicted pathological endpoints. Our data indicate MSCs, ES-CPCs, and nCPCs significantly reverse the PAB-altered proteome towards a pre-disease state in our animal model. These results indicate cell-based therapies show promise in improving RV function after pressure overload through partial restoration of the disease-altered cardiac proteome.Keywords
All Related Versions
Funding Information
- National Heart, Lung, and Blood Institute (1R01HL150562)
This publication has 39 references indexed in Scilit:
- Paracrine mechanisms of stem cell reparative and regenerative actions in the heartJournal of Molecular and Cellular Cardiology, 2011
- Transcoronary Bone Marrow‐Derived Progenitor Cells in a Child With Myocardial Infarction: First Pediatric ExperienceClinical Cardiology, 2010
- New Insights Into Paracrine Mechanisms of Human Cardiac Progenitor CellsEuropean Journal of Heart Failure, 2010
- Reduction of four-and-a-half LIM-protein 2 expression occurs in human left ventricular failure and leads to altered localization and reduced activity of metabolic enzymesThe Journal of Thoracic and Cardiovascular Surgery, 2009
- Latest insights in therapeutic options for systemic right ventricular failure: a comparison with left ventricular failureHeart, 2008
- Noninherited Risk Factors and Congenital Cardiovascular Defects: Current KnowledgeCirculation, 2007
- Right Ventricular Function and FailureCirculation, 2006
- Human Umbilical Cord Blood Mononuclear Cells for the Treatment of Acute Myocardial InfarctionCell Transplantation, 2004
- Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypesJACC, 2001
- Mechanical and neuroendocrine regulation of the endocrine heartCardiovascular Research, 1996